<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: The Virtual World Creeps into Pharma</title>
	<atom:link href="http://blog.pharmtech.com/2008/06/24/the-virtual-world-creeps-into-pharma/feed/" rel="self" type="application/rss+xml" />
	<link>http://blog.pharmtech.com/2008/06/24/the-virtual-world-creeps-into-pharma/</link>
	<description>The blog of Pharmaceutical Technology magazine</description>
	<lastBuildDate>Tue, 07 Feb 2012 17:25:13 -0500</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: Marco Viceconti</title>
		<link>http://blog.pharmtech.com/2008/06/24/the-virtual-world-creeps-into-pharma/comment-page-1/#comment-4039</link>
		<dc:creator>Marco Viceconti</dc:creator>
		<pubDate>Wed, 06 Aug 2008 10:57:41 +0000</pubDate>
		<guid isPermaLink="false">http://blog.pharmtech.com/?p=114#comment-4039</guid>
		<description>Every time you take an airplane you are trusting on something that was first designed using virtual models.  There is no difference.  

No drug will be verified only on virtual models, the final verifications will be done exactly as they are done today, with randomised controlled clinical studies.  

However, the difference is that before we enter animal and human experimentation, we shall have already screened away many candidate molecules that could be dangerous and/or ineffective. This will reduce the cost of drug development, improve the time-to-market, and make feasible a more personalised medicine, reduce the animal experimentation, and increase the safety of clinical trial.

Marco Viceconti
Scientific Coordinator, STEP Europhysiome initiative</description>
		<content:encoded><![CDATA[<p>Every time you take an airplane you are trusting on something that was first designed using virtual models.  There is no difference.  </p>
<p>No drug will be verified only on virtual models, the final verifications will be done exactly as they are done today, with randomised controlled clinical studies.  </p>
<p>However, the difference is that before we enter animal and human experimentation, we shall have already screened away many candidate molecules that could be dangerous and/or ineffective. This will reduce the cost of drug development, improve the time-to-market, and make feasible a more personalised medicine, reduce the animal experimentation, and increase the safety of clinical trial.</p>
<p>Marco Viceconti<br />
Scientific Coordinator, STEP Europhysiome initiative</p>
]]></content:encoded>
	</item>
</channel>
</rss>

